Argenx: HC Wainwright raises Buy rating, PT to $774 from $720.
ByAinvest
Friday, Aug 1, 2025 6:32 am ET1min read
ARGX--
July 02, 2025 — In a significant move for Argenx SE (NASDAQ:ARGX), H.C. Wainwright has upgraded the biotech company's stock to a Buy rating and raised the price target to $774 from $720. This update comes amidst strong progress in Argenx's neuromuscular treatment pipeline and positive second-quarter financial results [1].
Douglas Tsao, an analyst at H.C. Wainwright, cited the company's advancements in the ARGX-119 molecule, which has entered a registrational trial for congenital myasthenic syndromes (CMS). The Phase 1b results demonstrated promising safety and efficacy, boosting investor confidence. ARGX-119 is the third molecule from Argenx to reach late-stage clinical development, further solidifying the company's position in the biotech sector [1].
Additionally, Argenx reported robust second-quarter financials, with Vyvgart revenues reaching $949 million, representing a 20% quarter-over-quarter growth. This performance exceeded both BofA Securities' estimates and consensus expectations. The company's strong global demand growth and the launch of its pre-filled syringe option for at-home dosing contributed to the impressive results [2].
The upgrade reflects the positive outlook on Argenx's pipeline and financial performance. The company's strong balance sheet and profitability metrics also contribute to its appeal among investors. Despite the FDA's evaluation of potential risks associated with Vyvgart Hytrulo, Argenx continues to make strides in its treatment offerings, with the ARGX-119 molecule being a key driver of growth.
References
[1] https://finance.yahoo.com/news/h-c-wainwright-reaffirms-buy-042135381.html
[2] https://za.investing.com/news/analyst-ratings/bofa-securities-raises-argenx-stock-price-target-to-880-on-strong-vyvgart-sales-93CH-3814719
Argenx: HC Wainwright raises Buy rating, PT to $774 from $720.
Title: Argenx: HC Wainwright Raises Buy Rating, Target Price to $774July 02, 2025 — In a significant move for Argenx SE (NASDAQ:ARGX), H.C. Wainwright has upgraded the biotech company's stock to a Buy rating and raised the price target to $774 from $720. This update comes amidst strong progress in Argenx's neuromuscular treatment pipeline and positive second-quarter financial results [1].
Douglas Tsao, an analyst at H.C. Wainwright, cited the company's advancements in the ARGX-119 molecule, which has entered a registrational trial for congenital myasthenic syndromes (CMS). The Phase 1b results demonstrated promising safety and efficacy, boosting investor confidence. ARGX-119 is the third molecule from Argenx to reach late-stage clinical development, further solidifying the company's position in the biotech sector [1].
Additionally, Argenx reported robust second-quarter financials, with Vyvgart revenues reaching $949 million, representing a 20% quarter-over-quarter growth. This performance exceeded both BofA Securities' estimates and consensus expectations. The company's strong global demand growth and the launch of its pre-filled syringe option for at-home dosing contributed to the impressive results [2].
The upgrade reflects the positive outlook on Argenx's pipeline and financial performance. The company's strong balance sheet and profitability metrics also contribute to its appeal among investors. Despite the FDA's evaluation of potential risks associated with Vyvgart Hytrulo, Argenx continues to make strides in its treatment offerings, with the ARGX-119 molecule being a key driver of growth.
References
[1] https://finance.yahoo.com/news/h-c-wainwright-reaffirms-buy-042135381.html
[2] https://za.investing.com/news/analyst-ratings/bofa-securities-raises-argenx-stock-price-target-to-880-on-strong-vyvgart-sales-93CH-3814719
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet